Eli Lilly and Company (NYSE:LLY) Shares Sold by Parametrica Management Ltd

Parametrica Management Ltd cut its stake in Eli Lilly and Company (NYSE:LLY) by 80.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,184 shares of the company’s stock after selling 4,809 shares during the period. Eli Lilly and Company makes up 1.1% of Parametrica Management Ltd’s investment portfolio, making the stock its 24th largest position. Parametrica Management Ltd’s holdings in Eli Lilly and Company were worth $690,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Lipe & Dalton purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC purchased a new position in Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $8.64 during midday trading on Friday, hitting $733.51. 2,009,249 shares of the stock traded hands, compared to its average volume of 2,265,427. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business’s 50 day moving average price is $761.79 and its two-hundred day moving average price is $666.06.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 earnings per share. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Finally, Truist Financial restated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.